Scott F. Marshall

Liverpool, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 42 publications

Pharmacometric Model-Based Sample Size Allocation for a Region of Interest in a Multi-Regional Phase 2 Trial: A Case Study of an Anti-Psoriatic Drug.

Pharmacometric Model-Based Sample Size Allocation for a Region of Interest in a Multi-Regional Phase 2 Trial: A Case Study of an Anti-Psoriatic Drug.

Journal: CPT: pharmacometrics & systems pharmacology

Published: March 10, 2025

Incorporating Multiple Imputation Into Tanezumab Dose-Response Modeling of WOMAC Pain CFB Across Six Randomized Placebo-Controlled Phase 3 Trials.

Incorporating Multiple Imputation Into Tanezumab Dose-Response Modeling of WOMAC Pain CFB Across Six Randomized Placebo-Controlled Phase 3 Trials.

Journal: CPT: pharmacometrics & systems pharmacology

Published: December 20, 2024

Surface sampling pre- and post-decontamination in UK hospital rooms occupied by a 2021 household cluster of clade IIb mpox cases.

Surface sampling pre- and post-decontamination in UK hospital rooms occupied by a 2021 household cluster of clade IIb mpox cases.

Journal: The Journal of hospital infection

Published: November 14, 2024

Targeting the MDM2-p53 Interaction with Siremadlin: A Promising Therapeutic Strategy for Treating TP53 Wild-Type Chronic Lymphocytic Leukemia.

Targeting the MDM2-p53 Interaction with Siremadlin: A Promising Therapeutic Strategy for Treating TP53 Wild-Type Chronic Lymphocytic Leukemia.

Journal: Cancers

Published: November 12, 2024

Outcomes with single-agent gilteritinib for relapsed or refractory FLT3-mutant AML after contemporary induction therapy.

Outcomes with single-agent gilteritinib for relapsed or refractory FLT3-mutant AML after contemporary induction therapy.

Journal: Blood advances

Published: June 18, 2024

RNA Sequencing Reveals Candidate Genes and Pathways Associated with Resistance to MDM2 Antagonist Idasanutlin in TP53 Wild-Type Chronic Lymphocytic Leukemia.

RNA Sequencing Reveals Candidate Genes and Pathways Associated with Resistance to MDM2 Antagonist Idasanutlin in TP53 Wild-Type Chronic Lymphocytic Leukemia.

Journal: Biomedicines

Published: May 20, 2024

Inter-regional pharmacokinetics and exposure-response analyses of belimumab in patients with system lupus erythematosus.

Inter-regional pharmacokinetics and exposure-response analyses of belimumab in patients with system lupus erythematosus.

Journal: British journal of clinical pharmacology

Published: April 16, 2024

Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy.

Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy.

Journal: Blood

Published: June 20, 2023

SF3B1 Mutations Are Associated with Resistance to Non-Genotoxic MDM2 Inhibition in Chronic Lymphocytic Leukemia.

SF3B1 Mutations Are Associated with Resistance to Non-Genotoxic MDM2 Inhibition in Chronic Lymphocytic Leukemia.

Journal: International journal of molecular sciences

Published: May 22, 2023

Model-Informed Drug Development: Steps Toward Harmonized Guidance.

Model-Informed Drug Development: Steps Toward Harmonized Guidance.

Journal: Clinical pharmacology and therapeutics

Published: May 10, 2023

Splicing Modulation Results in Aberrant Isoforms and Protein Products of p53 Pathway Genes and the Sensitization of B Cells to Non-Genotoxic MDM2 Inhibition.

Splicing Modulation Results in Aberrant Isoforms and Protein Products of p53 Pathway Genes and the Sensitization of B Cells to Non-Genotoxic MDM2 Inhibition.

Journal: International journal of molecular sciences

Published: December 16, 2022

Prediction of relative change in free nerve growth factor following subcutaneous administration of tanezumab, a novel monoclonal antibody to nerve growth factor.

Prediction of relative change in free nerve growth factor following subcutaneous administration of tanezumab, a novel monoclonal antibody to nerve growth factor.

Journal: CPT: pharmacometrics & systems pharmacology

Published: October 17, 2022

Showing 1-12 of 42

Last Updated: 09/26/2026